Literature DB >> 12875910

Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients.

C E Teunissen1, C D Dijkstra, C H Polman, E L J Hoogervorst, K von Bergmann, D Lütjohann.   

Abstract

The serum concentration of 24S-hydroxycholesterol reflecting brain cholesterol turnover may be a possible marker for neurodegeneration and demyelination in multiple sclerosis. Serum was analyzed for cholesterol precursors and oxysterols in multiple sclerosis patients of different clinical subtypes (n=20 each subtype) and in 37 healthy controls. Serum 24S-hydroxycholesterol levels were lower in primary progressive and in older relapsing remitting multiple sclerosis patients. Furthermore, serum levels of lathosterol were decreased in all clinical subtypes. The results are important given recent interest in statin treatment in multiple sclerosis, which will further decrease the cholesterol precursor and oxysterol levels. The decreased levels of brain specific and peripheral sterols indicate a role for cholesterol homeostasis in relation to the pathology of multiple sclerosis, at least in the primary progressive clinical subtype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12875910     DOI: 10.1016/s0304-3940(03)00667-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  32 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

2.  Simvastatin: Multiple Sclerosis.

Authors:  Joyce A Generali; Dennis J Cada
Journal:  Hosp Pharm       Date:  2015-06

Review 3.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

4.  High fat diet exacerbates neuroinflammation in an animal model of multiple sclerosis by activation of the Renin Angiotensin system.

Authors:  Silke Timmermans; Jeroen F J Bogie; Tim Vanmierlo; Dieter Lütjohann; Piet Stinissen; Niels Hellings; Jerome J A Hendriks
Journal:  J Neuroimmune Pharmacol       Date:  2013-09-26       Impact factor: 4.147

5.  Atorvastatin: multiple sclerosis.

Authors:  Joyce A Generali; Dennis J Cada
Journal:  Hosp Pharm       Date:  2014-11

Review 6.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 7.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

8.  Challenging behavior in Smith-Lemli-Opitz syndrome: initial test of biobehavioral influences.

Authors:  Kurt A Freeman; Rose Eagle; Louise S Merkens; Darryn Sikora; Kersti Pettit-Kekel; Mina Nguyen-Driver; Robert D Steiner
Journal:  Cogn Behav Neurol       Date:  2013-03       Impact factor: 1.600

Review 9.  Brain cholesterol metabolism, oxysterols, and dementia.

Authors:  Timothy M Hughes; Caterina Rosano; Rhobert W Evans; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Cross-talk between oxysterols and glucocorticoids: differential regulation of secreted phopholipase A2 and impact on oligodendrocyte death.

Authors:  Amalia Trousson; Joelle Makoukji; Patrice X Petit; Sophie Bernard; Christian Slomianny; Michael Schumacher; Charbel Massaad
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.